Individualization of treatments with drugs metabolized by CES1: combining genetics and metabolomics

Henrik Berg Rasmussen; Ditte Bjerre; Kristian Linnet; Gesche Jürgens; Kim Dalhoff; Hreinn Stefansson; Thomas Hankemeier; Rima Kaddurah-Daouk; Olivier Taboureau; Søren Brunak; Tine Houmann; Pia Jeppesen; Anne Katrine Pagsberg; Kerstin Plessen; Jørgen Dyrborg; Peter Riis Hansen; Poul Erik Hansen; Tim Hughes; Thomas Werge; INDICES Consortium

doi:10.2217/pgs.15.7

Individualization of treatments with drugs metabolized by CES1: combining genetics and metabolomics

Henrik Berg Rasmussen, Ditte Bjerre, Kristian Linnet, Gesche Jürgens, Kim Dalhoff, Hreinn Stefansson, Thomas Hankemeier, Rima Kaddurah-Daouk, Olivier Taboureau, Søren Brunak, Tine Houmann, Pia Jeppesen, Anne Katrine Pagsberg, Kerstin Plessen, Jørgen Dyrborg, Peter Riis Hansen, Poul Erik Hansen, Tim Hughes, Thomas Werge, INDICES Consortium

20 Citations (Scopus)

Abstract

CES1 is involved in the hydrolysis of ester group-containing xenobiotic and endobiotic compounds including several essential and commonly used drugs. The individual variation in the efficacy and tolerability of many drugs metabolized by CES1 is considerable. Hence, there is a large interest in individualizing the treatment with these drugs. The present review addresses the issue of individualized treatment with drugs metabolized by CES1. It describes the composition of the gene encoding CES1, reports variants of this gene with focus upon those with a potential effect on drug metabolism and provides an overview of the protein structure of this enzyme bringing notice to mechanisms involved in the regulation of enzyme activity. Subsequently, the review highlights drugs metabolized by CES1 and argues that individual differences in the pharmacokinetics of these drugs play an important role in determining drug response and tolerability suggesting prospects for individualized drug therapies. Our review also discusses endogenous substrates of CES1 and assesses the potential of using metabolomic profiling of blood to identify proxies for the hepatic activity of CES1 that predict the rate of drug metabolism. Finally, the combination of genetics and metabolomics to obtain an accurate prediction of the individual response to CES1-dependent drugs is discussed.

Original language	English
Journal	Pharmacogenomics
Volume	16
Issue number	6
Pages (from-to)	649-65
ISSN	1462-2416
DOIs	https://doi.org/10.2217/pgs.15.7
Publication status	Published - 1 Apr 2015

Keywords

Carboxylic Ester Hydrolases
Humans
Metabolomics
Pharmaceutical Preparations
Precision Medicine
Protein Structure, Secondary
Treatment Outcome

Access to Document

10.2217/pgs.15.7

Cite this

Rasmussen, H. B., Bjerre, D., Linnet, K., Jürgens, G., Dalhoff, K., Stefansson, H., Hankemeier, T., Kaddurah-Daouk, R., Taboureau, O., Brunak, S., Houmann, T., Jeppesen, P., Pagsberg, A. K., Plessen, K., Dyrborg, J., Hansen, P. R., Hansen, P. E., Hughes, T., Werge, T., & INDICES Consortium (2015). Individualization of treatments with drugs metabolized by CES1: combining genetics and metabolomics. Pharmacogenomics, 16(6), 649-65. https://doi.org/10.2217/pgs.15.7

Rasmussen, HB, Bjerre, D, Linnet, K, Jürgens, G, Dalhoff, K, Stefansson, H, Hankemeier, T, Kaddurah-Daouk, R, Taboureau, O, Brunak, S, Houmann, T, Jeppesen, P , Pagsberg, AK, Plessen, K, Dyrborg, J, Hansen, PR, Hansen, PE, Hughes, T, Werge, T & INDICES Consortium 2015, 'Individualization of treatments with drugs metabolized by CES1: combining genetics and metabolomics', Pharmacogenomics, vol. 16, no. 6, pp. 649-65. https://doi.org/10.2217/pgs.15.7

@article{9565d2383f8f4c2aa77c5e3051b38391,

title = "Individualization of treatments with drugs metabolized by CES1: combining genetics and metabolomics",

abstract = "CES1 is involved in the hydrolysis of ester group-containing xenobiotic and endobiotic compounds including several essential and commonly used drugs. The individual variation in the efficacy and tolerability of many drugs metabolized by CES1 is considerable. Hence, there is a large interest in individualizing the treatment with these drugs. The present review addresses the issue of individualized treatment with drugs metabolized by CES1. It describes the composition of the gene encoding CES1, reports variants of this gene with focus upon those with a potential effect on drug metabolism and provides an overview of the protein structure of this enzyme bringing notice to mechanisms involved in the regulation of enzyme activity. Subsequently, the review highlights drugs metabolized by CES1 and argues that individual differences in the pharmacokinetics of these drugs play an important role in determining drug response and tolerability suggesting prospects for individualized drug therapies. Our review also discusses endogenous substrates of CES1 and assesses the potential of using metabolomic profiling of blood to identify proxies for the hepatic activity of CES1 that predict the rate of drug metabolism. Finally, the combination of genetics and metabolomics to obtain an accurate prediction of the individual response to CES1-dependent drugs is discussed.",

keywords = "Carboxylic Ester Hydrolases, Humans, Metabolomics, Pharmaceutical Preparations, Precision Medicine, Protein Structure, Secondary, Treatment Outcome",

author = "Rasmussen, {Henrik Berg} and Ditte Bjerre and Kristian Linnet and Gesche J{\"u}rgens and Kim Dalhoff and Hreinn Stefansson and Thomas Hankemeier and Rima Kaddurah-Daouk and Olivier Taboureau and S{\o}ren Brunak and Tine Houmann and Pia Jeppesen and Pagsberg, {Anne Katrine} and Kerstin Plessen and J{\o}rgen Dyrborg and Hansen, {Peter Riis} and Hansen, {Poul Erik} and Tim Hughes and Thomas Werge and {INDICES Consortium}",

year = "2015",

month = apr,

day = "1",

doi = "10.2217/pgs.15.7",

language = "English",

volume = "16",

pages = "649--65",

journal = "Pharmacogenomics",

issn = "1462-2416",

publisher = "Future Medicine Ltd.",

number = "6",

}

TY - JOUR

T1 - Individualization of treatments with drugs metabolized by CES1

T2 - combining genetics and metabolomics

AU - Rasmussen, Henrik Berg

AU - Bjerre, Ditte

AU - Linnet, Kristian

AU - Jürgens, Gesche

AU - Dalhoff, Kim

AU - Stefansson, Hreinn

AU - Hankemeier, Thomas

AU - Kaddurah-Daouk, Rima

AU - Taboureau, Olivier

AU - Brunak, Søren

AU - Houmann, Tine

AU - Jeppesen, Pia

AU - Pagsberg, Anne Katrine

AU - Plessen, Kerstin

AU - Dyrborg, Jørgen

AU - Hansen, Peter Riis

AU - Hansen, Poul Erik

AU - Hughes, Tim

AU - Werge, Thomas

AU - INDICES Consortium

PY - 2015/4/1

Y1 - 2015/4/1

N2 - CES1 is involved in the hydrolysis of ester group-containing xenobiotic and endobiotic compounds including several essential and commonly used drugs. The individual variation in the efficacy and tolerability of many drugs metabolized by CES1 is considerable. Hence, there is a large interest in individualizing the treatment with these drugs. The present review addresses the issue of individualized treatment with drugs metabolized by CES1. It describes the composition of the gene encoding CES1, reports variants of this gene with focus upon those with a potential effect on drug metabolism and provides an overview of the protein structure of this enzyme bringing notice to mechanisms involved in the regulation of enzyme activity. Subsequently, the review highlights drugs metabolized by CES1 and argues that individual differences in the pharmacokinetics of these drugs play an important role in determining drug response and tolerability suggesting prospects for individualized drug therapies. Our review also discusses endogenous substrates of CES1 and assesses the potential of using metabolomic profiling of blood to identify proxies for the hepatic activity of CES1 that predict the rate of drug metabolism. Finally, the combination of genetics and metabolomics to obtain an accurate prediction of the individual response to CES1-dependent drugs is discussed.

AB - CES1 is involved in the hydrolysis of ester group-containing xenobiotic and endobiotic compounds including several essential and commonly used drugs. The individual variation in the efficacy and tolerability of many drugs metabolized by CES1 is considerable. Hence, there is a large interest in individualizing the treatment with these drugs. The present review addresses the issue of individualized treatment with drugs metabolized by CES1. It describes the composition of the gene encoding CES1, reports variants of this gene with focus upon those with a potential effect on drug metabolism and provides an overview of the protein structure of this enzyme bringing notice to mechanisms involved in the regulation of enzyme activity. Subsequently, the review highlights drugs metabolized by CES1 and argues that individual differences in the pharmacokinetics of these drugs play an important role in determining drug response and tolerability suggesting prospects for individualized drug therapies. Our review also discusses endogenous substrates of CES1 and assesses the potential of using metabolomic profiling of blood to identify proxies for the hepatic activity of CES1 that predict the rate of drug metabolism. Finally, the combination of genetics and metabolomics to obtain an accurate prediction of the individual response to CES1-dependent drugs is discussed.

KW - Carboxylic Ester Hydrolases

KW - Humans

KW - Metabolomics

KW - Pharmaceutical Preparations

KW - Precision Medicine

KW - Protein Structure, Secondary

KW - Treatment Outcome

U2 - 10.2217/pgs.15.7

DO - 10.2217/pgs.15.7

M3 - Review

C2 - 25896426

SN - 1462-2416

VL - 16

SP - 649

EP - 665

JO - Pharmacogenomics

JF - Pharmacogenomics

IS - 6

ER -

Individualization of treatments with drugs metabolized by CES1: combining genetics and metabolomics

Abstract

Keywords

Access to Document

Fingerprint

Cite this